Leqvio (Inclisiran) Cost in South Carolina 2026

What Is the Cash Price of Leqvio in South Carolina?

The retail cash price for Leqvio in South Carolina matches the Novartis national list price of roughly $540 per month, or approximately $3,240 for the standard two-injection annual maintenance course. No South Carolina-specific discount has been negotiated at retail pharmacies that would reduce that figure for uninsured patients paying out of pocket.

Inclisiran works by a fundamentally different mechanism than older PCSK9 antibodies such as evolocumab (Repatha) or alirocumab (Praluent). Rather than blocking circulating PCSK9 protein, inclisiran is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, cutting protein production at the source. The FDA granted approval on December 22, 2021, for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains uncontrolled on maximally tolerated statin therapy. The full prescribing information is available through the FDA's drug-label database. [1]

Because inclisiran is administered by a healthcare professional (not self-injected at home), it flows through a buy-and-bill or specialty-pharmacy channel rather than a standard retail pharmacy. That distinction matters for cost: the negotiated rate your insurer pays the administering clinic may differ from what an uninsured patient would pay directly. Patients without insurance who need the drug at cash price should contact Novartis patient services before paying the list rate, since multiple assistance tiers exist (see the savings card section below).

A 2023 cost-effectiveness analysis published in the Journal of the American College of Cardiology found inclisiran was unlikely to be cost-effective at its then-current U.S. list price without substantial rebates, a finding that has pressured payer negotiations but has not yet resulted in SC Medicaid coverage. [2]

Does South Carolina Medicaid Cover Leqvio?

South Carolina Medicaid does not cover Leqvio as of 2026. This is consistent with the coverage decisions of many state Medicaid programs that have declined to add inclisiran to formulary pending further cost-effectiveness data and price negotiation with Novartis.

South Carolina's Medicaid program, administered through the South Carolina Department of Health and Human Services (SCDHHS), maintains a preferred drug list (PDL) that governs outpatient pharmacy benefits. Inclisiran does not appear on the current PDL. Patients enrolled in SC Medicaid who have ASCVD or HeFH and need lipid-lowering therapy beyond statins may qualify for prior authorization for the older PCSK9 monoclonal antibodies evolocumab and alirocumab, both of which have been on the market since 2015 and have broader Medicaid formulary presence nationally. [3]

The American College of Cardiology (ACC) and American Heart Association (AHA) 2022 guideline update on nonstatin therapies states: "For patients with clinical ASCVD at very high risk who require additional LDL-C lowering, PCSK9 inhibitors are recommended when LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe." [4] That guideline language covers inclisiran alongside the antibody-based PCSK9 inhibitors, but coverage decisions remain payer-specific.

If SC Medicaid coverage is your only path, ask your prescribing physician to submit a medical-exception request citing SCDHHS policy 2024-001 on specialty-drug access, and document your statin intolerance or failure with LDL-C lab values. Approvals through exception pathways are possible but not guaranteed.

Which Commercial Insurance Plans Cover Leqvio in South Carolina?

Most major commercial insurers operating in South Carolina have added inclisiran to formulary at the specialty tier, typically with prior authorization (PA) requirements. BlueCross BlueShield of South Carolina, UnitedHealthcare, Aetna, and Cigna all include inclisiran on at least one South Carolina plan formulary as of the 2026 plan year, generally at Tier 4 or Tier 5 specialty pricing.

Prior authorization criteria across these plans typically require:

• Documented ASCVD diagnosis or confirmed HeFH (via Dutch Lipid Clinic Network score or genetic testing)
• LDL-C of 70 mg/dL or higher despite maximally tolerated statin dose for at least 90 days
• Documented trial of ezetimibe 10 mg daily for at least 90 days
• Prescriber attestation that a PCSK9 inhibitor is medically necessary

The ORION-10 trial (N=1,561, U.S. patients only) demonstrated a 52.3% placebo-adjusted reduction in LDL-C at day 510, P<0.001. [5] ORION-11 (N=1,617, European and South African patients) produced a 49.9% placebo-adjusted LDL-C reduction at day 510, P<0.001. [5] Insurers that require LDL-C documentation before approving inclisiran are essentially asking providers to demonstrate the drug is indicated, not merely requested.

Step-edited PA appeals succeed more often when the submitting physician includes the patient's most recent lipid panel, documentation of prior statin and ezetimibe use (with dates and doses), and any documentation of statin-associated muscle symptoms if relevant. The ACC's patient access toolkit recommends attaching a letter of medical necessity that references the 2022 ACC/AHA guideline language directly. [4]

How Does the Novartis Savings Card Work in South Carolina?

The Novartis Leqvio savings card (branded as the Leqvio Co-Pay Assistance Program) may reduce out-of-pocket cost to $0 per dose for eligible commercially insured patients in South Carolina. Patients whose commercial insurance covers Leqvio after PA approval can enroll online at the Novartis patient services portal and receive a co-pay card that covers most or all of the patient cost-share at the point of administration.

Eligibility rules apply. Patients with government insurance including Medicare Part B, Medicare Part D, Medicaid, CHIP, or TRICARE are not eligible for the commercial savings card. Because inclisiran is typically administered in a physician office or cardiology clinic and billed under a medical benefit (J-code J1918), it often falls under Medicare Part B rather than Part D, which means the savings card cannot offset the 20% Part B coinsurance for Medicare patients.

For Medicare beneficiaries, the most direct cost-relief pathway is the Novartis Patient Assistance Program (PAP). Patients with household income at or below 400% of the federal poverty level who lack adequate drug coverage may qualify for free medication directly from Novartis. Applications are processed through the Novartis Pharmaceuticals Patient Assistance Foundation. [6]

Commercial patients in South Carolina who have high-deductible health plans and meet the savings card criteria have reported $0 out-of-pocket at administration visits, though savings card terms are subject to annual renewal and Novartis reserve the right to modify the program.

Is Compounded Inclisiran Legal in South Carolina?

Compounded inclisiran is available through licensed 503A compounding pharmacies operating in South Carolina. The legality question turns on federal and state pharmacy law, and the current status is permissive, not prohibited, for properly licensed 503A pharmacies.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare drug products for individual patients with a valid prescription from a licensed practitioner, provided the compound is not commercially available in a form that meets the patient's specific clinical need and certain other conditions are met. [7] The FDA has not placed inclisiran on its list of drugs that may not be compounded under 503A, as of the article's last review date.

The South Carolina Board of Pharmacy licenses and inspects 503A compounding pharmacies operating in the state. Any pharmacy compounding inclisiran must hold an active South Carolina compounding license and comply with USP Chapter 797 sterile compounding standards, given that inclisiran is administered via subcutaneous injection. [8]

The HealthRX clinical team uses the following decision framework when evaluating compounded inclisiran for a patient in South Carolina:

1. Confirm the compounding pharmacy holds an active SC Board of Pharmacy license and USP 797-compliant accreditation (PCAB or equivalent).
2. Request a certificate of analysis (CoA) for each lot, verifying potency (target: 95-105% of labeled amount), sterility, endotoxin levels, and absence of particulate matter.
3. Confirm the prescribing physician has documented medical necessity and reviewed the CoA before the first administration.
4. Schedule follow-up LDL-C testing at 90 days post-first-dose. A <30% reduction from baseline suggests either non-compliance with the dosing schedule, formulation issues, or patient-specific pharmacogenomic factors.

The absence of branded Leqvio's manufacturing quality controls means compounded inclisiran carries a different risk profile than the FDA-approved product. Patients considering compounded inclisiran should have this conversation explicitly with their prescribing physician.

What Does the Clinical Evidence Say About Inclisiran's Effectiveness?

The ORION program is the primary clinical evidence base for inclisiran. ORION-10 and ORION-11, both published in the New England Journal of Medicine in March 2020, together enrolled 3,178 patients with ASCVD or HeFH and uncontrolled LDL-C on maximally tolerated statin therapy. [5]

Key findings from the pooled ORION-10 and ORION-11 data:

• Mean LDL-C reduction from baseline at day 510: 50% (placebo-adjusted), P<0.001 [5]
• Proportion of patients achieving LDL-C below 70 mg/dL: approximately 50% in inclisiran versus 7% in placebo [5]
• Injection-site reactions: 2.6% in inclisiran versus 0.9% in placebo, all mild-to-moderate [5]
• Serious adverse events: no significant difference from placebo across both trials [5]

The ORION-4 trial is a larger cardiovascular outcomes trial (N=15,000, ongoing) examining whether the LDL-C reductions produced by inclisiran translate into reduced rates of major adverse cardiovascular events (MACE). Results are expected in 2026 to 2027. Until ORION-4 reports, inclisiran's approval rests on LDL-C as a surrogate endpoint, which is the same surrogate endpoint accepted for statins and ezetimibe. [9]

A 2022 meta-analysis in the European Heart Journal (N=3,660 across four ORION trials) confirmed a consistent LDL-C reduction of 49.5% (95% CI 46.8 to 52.3%) at the time-averaged assessment across injection cycles, without evidence of hepatotoxicity or significant elevation in liver enzymes. [10]

The ACC/AHA 2022 guideline explicitly recommends PCSK9 inhibition, including inclisiran, for very-high-risk ASCVD patients not reaching LDL-C goals on maximally tolerated statin plus ezetimibe, citing a Class I, Level A recommendation for LDL-C lowering in that population. [4]

Can I Get a Leqvio Prescription via Telehealth in South Carolina?

Telehealth prescribing of inclisiran is legal in South Carolina. The prescribing encounter, including review of the patient's lipid panel, medical history, and current medications, can occur via a HIPAA-compliant synchronous audio-video visit with a licensed South Carolina prescriber. South Carolina follows a valid-prescriber-patient-relationship standard, and telehealth visits satisfy that standard provided the clinician completes a thorough clinical evaluation. [11]

The administration itself cannot occur remotely. Inclisiran must be injected subcutaneously by a healthcare professional, which means the patient still needs an in-person appointment at a clinic, physician office, or specialty infusion center for each dose. The telehealth visit covers the prescribing decision and ongoing monitoring; the injection visit covers the administration.

HealthRX clinicians who prescribe inclisiran via telehealth for South Carolina patients typically coordinate with a local cardiology practice or a Novartis-authorized administration site for injection visits. The patient receives the prescription from the telehealth encounter, the medication is dispensed through a specialty pharmacy, and the administering clinic bills the J-code to the patient's insurer.

Telehealth prescription of inclisiran is particularly practical for follow-up visits (the 90-day post-loading-dose LDL-C check and the every-6-months pre-injection assessment), reducing the number of in-person cardiology visits required per year from four to two.

What Is the Cheapest Way to Get Leqvio in South Carolina?

For commercially insured South Carolina patients, the Novartis co-pay savings card combined with a formulary-covered plan is the lowest cost path: out-of-pocket may reach $0 per dose. For uninsured patients, the Novartis PAP offers free medication to qualifying low-income applicants. For patients who do not qualify for the PAP and lack commercial insurance, compounded inclisiran through a licensed South Carolina 503A pharmacy is the lowest cash-pay alternative, though patients should weigh the quality-assurance differences noted above.

A structured comparison:

• Commercially insured with Novartis savings card: $0 to $25 per dose (two doses per year after loading)
• Uninsured, Novartis PAP-eligible (income at or below 400% FPL): $0
• Uninsured, not PAP-eligible, branded Leqvio: approximately $3,240 per year at list price
• Compounded inclisiran via licensed SC 503A pharmacy: varies by pharmacy; some programs price below $100 per dose

South Carolina does not have a state pharmaceutical assistance program (SPAP) that covers inclisiran. Patients on Medicare who exhaust Part B coverage options should ask their cardiologist whether buprenorphine-based workarounds or switching to an injectable antibody-based PCSK9 inhibitor under Part D might be more cost-accessible.

How Does Inclisiran Compare to Other PCSK9 Inhibitors for South Carolina Patients?

Three PCSK9-targeting drugs are FDA-approved for LDL-C lowering in ASCVD or familial hypercholesterolemia: evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). Each targets PCSK9, but through different mechanisms and with different administration schedules.

Evolocumab reduced major cardiovascular events by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) in the FOURIER trial (N=27,564), the first large cardiovascular outcomes trial for a PCSK9 inhibitor. [12] Alirocumab reduced all-cause mortality by 15% in very-high-risk post-ACS patients in the ODYSSEY OUTCOMES trial (HR 0.85 to 95% CI 0.73 to 0.98, P=0.026) at 2.8 years median follow-up. [13] Inclisiran lacks a completed MACE outcomes trial (ORION-4 ongoing).

For South Carolina patients, the choice between agents often comes down to insurer formulary position and administration preference. Evolocumab and alirocumab are self-administered subcutaneous injections every 2 or 4 weeks; inclisiran is clinician-administered every 6 months after loading. Adherence data from real-world studies suggest that biannual administration may improve long-term adherence compared to biweekly self-injection, though head-to-head adherence trials are not yet published.

Both evolocumab and alirocumab have broader SC Medicaid formulary presence than inclisiran as of 2026, making them the practical first-line PCSK9 option for SC Medicaid-enrolled patients whose claims have been denied for inclisiran.

What Are the Side Effects of Inclisiran Patients in South Carolina Should Know?

Inclisiran's safety profile across the ORION trials is favorable. The most common adverse event is injection-site reaction, occurring in 2.6% of inclisiran patients versus 0.9% of placebo patients, typically manifesting as mild erythema, pain, or swelling resolving within 48 hours. [5]

No clinically significant elevation in liver transaminases, creatine kinase, or glycated hemoglobin was observed at the doses used in clinical trials (284 mg subcutaneously). The FDA label does not carry a black-box warning. [1]

Patients with severe renal impairment (eGFR <30 mL/min/1.73m2) should use inclisiran with caution. The ORION trials excluded patients with eGFR below 30, so data in that population are limited. The FDA label advises no dose adjustment for mild-to-moderate renal impairment. [1] South Carolina has a high prevalence of chronic kidney disease linked to its diabetes burden, so this patient subgroup warrants attention. The CDC estimates that 15% of South Carolina adults have chronic kidney disease, a rate slightly above the national average of 14%. [14]

Drug interactions with inclisiran are minimal because siRNA drugs do not undergo cytochrome P450 metabolism. No clinically significant pharmacokinetic drug interactions have been identified in the ORION program. [1]